Vessi Medical, a Misgav, Israel-based developer of a cryoablation solution for superficial bladder cancer, secured $1.7m in funding.
Participating in the financing were Agriline, The Trendlines Group, the Israel Innovation Authority, and ExitValley investors.
The company intends to use the funds to continue to develop its intravesical cryotherapy device, whose first-in-human (FIH) study demonstrating safety and efficacy is planned for Q1 2021.
Led by CEO Eyal Kochavi, Vessi Medical is advancing a minimally invasive ablation solution for superficial bladder cancer (or non-muscle invasive bladder cancer – “NMIBC”) expected to improve quality of life for people globally suffering from NMIBC.
The Vessi system consists of a standalone console and a disposable device inserted transurethrally into the bladder.